JPH11243910A - Food composition for prevention of periodontal diseases and for prevention of advance of periodontal diseases - Google Patents
Food composition for prevention of periodontal diseases and for prevention of advance of periodontal diseasesInfo
- Publication number
- JPH11243910A JPH11243910A JP10052355A JP5235598A JPH11243910A JP H11243910 A JPH11243910 A JP H11243910A JP 10052355 A JP10052355 A JP 10052355A JP 5235598 A JP5235598 A JP 5235598A JP H11243910 A JPH11243910 A JP H11243910A
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- extract
- food composition
- antibacterial
- highly soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 235000013305 food Nutrition 0.000 title claims abstract description 37
- 208000028169 periodontal disease Diseases 0.000 title claims abstract description 35
- 230000002265 prevention Effects 0.000 title description 4
- 239000000284 extract Substances 0.000 claims abstract description 63
- 244000269722 Thea sinensis Species 0.000 claims abstract description 24
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 20
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 20
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 14
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 14
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 14
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 14
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 13
- 244000068988 Glycine max Species 0.000 claims abstract description 13
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000001527 calcium lactate Substances 0.000 claims abstract description 12
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 12
- 229960002401 calcium lactate Drugs 0.000 claims abstract description 12
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 12
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 57
- 239000000419 plant extract Substances 0.000 claims description 47
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 35
- 229960005069 calcium Drugs 0.000 claims description 35
- 239000011575 calcium Substances 0.000 claims description 35
- 229910052791 calcium Inorganic materials 0.000 claims description 35
- 229940069445 licorice extract Drugs 0.000 claims description 24
- 235000003687 soy isoflavones Nutrition 0.000 claims description 21
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 10
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 10
- 239000000811 xylitol Substances 0.000 claims description 10
- 235000010447 xylitol Nutrition 0.000 claims description 10
- 229960002675 xylitol Drugs 0.000 claims description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 10
- 239000007910 chewable tablet Substances 0.000 claims description 9
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000000845 maltitol Substances 0.000 claims description 7
- 235000010449 maltitol Nutrition 0.000 claims description 7
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 7
- 229940035436 maltitol Drugs 0.000 claims description 7
- 239000004386 Erythritol Substances 0.000 claims description 6
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 235000019414 erythritol Nutrition 0.000 claims description 6
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 6
- 229940009714 erythritol Drugs 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 6
- 229930003448 Vitamin K Natural products 0.000 claims description 5
- 229940068682 chewable tablet Drugs 0.000 claims description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 5
- 150000005846 sugar alcohols Chemical class 0.000 claims description 5
- 235000019168 vitamin K Nutrition 0.000 claims description 5
- 239000011712 vitamin K Substances 0.000 claims description 5
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 5
- 229940046010 vitamin k Drugs 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 4
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 4
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 4
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 4
- 229960002079 calcium pantothenate Drugs 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 230000005750 disease progression Effects 0.000 claims description 4
- 229960005431 ipriflavone Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 229960002920 sorbitol Drugs 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 4
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 229960002713 calcium chloride Drugs 0.000 claims description 3
- 235000011148 calcium chloride Nutrition 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 229940043430 calcium compound Drugs 0.000 abstract 1
- 150000001674 calcium compounds Chemical class 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 description 23
- 239000000463 material Substances 0.000 description 19
- 235000013616 tea Nutrition 0.000 description 19
- 229940009387 calcium gluconate / calcium lactate Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000000214 mouth Anatomy 0.000 description 9
- 239000008399 tap water Substances 0.000 description 9
- 235000020679 tap water Nutrition 0.000 description 9
- 208000006386 Bone Resorption Diseases 0.000 description 8
- 230000024279 bone resorption Effects 0.000 description 8
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 6
- -1 isoflavone glycosides Chemical class 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000003239 periodontal effect Effects 0.000 description 6
- 108010011485 Aspartame Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241000202807 Glycyrrhiza Species 0.000 description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000000605 aspartame Substances 0.000 description 5
- 235000010357 aspartame Nutrition 0.000 description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 5
- 229960003438 aspartame Drugs 0.000 description 5
- 210000003679 cervix uteri Anatomy 0.000 description 5
- 229940010454 licorice Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000006539 genistein Nutrition 0.000 description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 4
- 229940045109 genistein Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 3
- 239000001354 calcium citrate Substances 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000007240 daidzein Nutrition 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000013337 tricalcium citrate Nutrition 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 2
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940036811 bone meal Drugs 0.000 description 2
- 239000002374 bone meal Substances 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940053326 magnesium salt Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、新規な歯周病予防
又は歯周病進行予防食品組成物に関する。The present invention relates to a novel food composition for preventing periodontal disease or preventing periodontal disease progression.
【０００２】[0002]
【従来の技術】歯周病は、特定の歯周病原菌による感染
症であり、歯周病原菌として知られている細菌として
は、ポリフィロモナス・ジンジバリスに代表されるグラ
ム陰性嫌気性細菌が挙げられる。これらの細菌は、口腔
内で、歯頸部の根面に付着したプラークの中で増殖し、
周辺の歯肉や歯根膜、歯槽骨を含む組織領域に慢性的な
炎症を惹起することにより、歯周病を発症させる。この
ような観点から、歯周病を予防する手段の一つとして、
抗菌剤を用いて歯周病原菌を抑える試みがなされてお
り、従来、クロルヘキシジンや塩化セチルピリジニウム
などの合成抗菌剤が歯磨やマウスウォッシュに配合さ
れ、その効果が確認されている。さらに、これらの合成
抗菌剤は、口中錠（トローチ）にも配合され、口中やの
どにおける殺菌を意図する医薬品が市販されている。2. Description of the Related Art Periodontal disease is an infectious disease caused by a specific periodontal pathogen. Examples of bacteria known as periodontal pathogens include gram-negative anaerobic bacteria represented by Polyphyromonas gingivalis. . These bacteria grow in the oral cavity in plaques attached to the root surface of the cervix,
It causes periodontal disease by inducing chronic inflammation in the surrounding tissue region including the gums, periodontal ligament and alveolar bone. From such a viewpoint, as one of the means to prevent periodontal disease,
Attempts have been made to suppress periodontal pathogens using antibacterial agents. Conventionally, synthetic antibacterial agents such as chlorhexidine and cetylpyridinium chloride have been added to toothpastes and mouthwashes, and their effects have been confirmed. Furthermore, these synthetic antibacterial agents are also compounded in lozenges (troches), and pharmaceuticals intended for sterilization in the mouth and throat are commercially available.
【０００３】しかし、歯周病は一旦発生すると再発しや
すい傾向のある口腔疾患であるので、薬剤を長期間使用
することが考えられ、かかる場合には安全性の高い抗菌
剤を使う方が好ましい。However, since periodontal disease is an oral disease that tends to recur once it occurs, it is conceivable to use the drug for a long time. In such a case, it is preferable to use a highly safe antibacterial agent. .
【０００４】さらに、最近では、食品として摂取可能な
植物抽出物の中に、人体には安全であり、かつ、歯周病
原菌に対しては抗菌力を示す植物系天然素材が、いくつ
か見出されてきている。特に、油溶性甘草抽出物、ゲニ
ステイン、茶ポリフェノール抽出物のような素材は、イ
ンビトロ系で、歯周病原菌に対する抗菌作用、付着阻害
作用が見出されている（特開平07-157417号公報、特開
平04-164021号公報、特開平04-283518号公報、特開昭63
-267714号公報、特開平5-944号公報）。しかし、前述の
合成系抗菌剤に比べると、抗菌力は１／１０倍から１／
１００倍程度も弱く、効果のある口腔での濃度域が高す
ぎるため、実効面で歯周病への有用性を十分に期待でき
るものではなかった。[0004] Furthermore, recently, among plant extracts that can be ingested as foods, some plant-based natural materials that are safe for the human body and exhibit antibacterial activity against periodontal pathogens have been found. Have been. In particular, materials such as oil-soluble licorice extract, genistein, and tea polyphenol extract have been found to have an antibacterial action against periodontopathic bacteria and an adhesion inhibitory action in an in vitro system (Japanese Patent Application Laid-Open No. 07-157417, JP-A-04-164021, JP-A-04-283518, JP-A-63
-267714, JP-A-5-944). However, as compared with the aforementioned synthetic antibacterial agents, the antibacterial activity is 1/10 to 1 /
It is about 100 times weaker and the effective concentration range in the oral cavity is too high, so that its usefulness for periodontal disease cannot be fully expected in terms of effective surface.
【０００５】一方、歯周病は、歯周病原菌の惹起した慢
性的な炎症により、歯を支えている歯槽骨の吸収が進行
する疾患であり、先進国では歯を失う最大の原因となっ
ている。また、カルシウムは、成長期の子供、妊娠期の
女性などにおいて、歯槽骨の骨カルシウム濃度を維持も
しくは強化するために必要な栄養成分であることが周知
であり（文献「ビタミンＤ欠乏による歯槽骨の変化に関
するＸ線的，光顕的および走査型電顕的研究」九州歯科
学会雑誌４６，６７−８８，１９９２年）、カルシウム
補充食品類が多数提供されている。一部の特定のカルシ
ウム塩（パントテン酸カルシウム）は、歯周病に関連す
る歯槽骨吸収を抑制することが知られている（特開平08
-133969号公報）。このように、カルシウムおよびカル
シウム塩の摂取が歯周病に対し、ある程度の予防的効果
を上げることは認められているが、前述のように、歯周
病の原因である歯周病原菌の歯周組織に対する傷害的な
強い刺激作用が取り除かれない以上、予防ないしは治療
効果を期待することは困難である。[0005] On the other hand, periodontal disease is a disease in which the resorption of alveolar bone supporting teeth progresses due to chronic inflammation caused by periodontal pathogens, and is the largest cause of tooth loss in developed countries. I have. It is well known that calcium is a nutritional component necessary for maintaining or enhancing alveolar bone calcium concentration in growing children, pregnant women, and the like (refer to the document "Alveolar bone due to vitamin D deficiency"). X-ray, light microscopic and scanning electron microscopic studies on the change of liposomes ", Journal of Kyushu Dental Society, 46, 67-88, 1992), and many calcium supplemented foods are provided. Some specific calcium salts (calcium pantothenate) are known to suppress alveolar bone resorption associated with periodontal disease (Japanese Patent Application Laid-Open No.
-133969). As described above, it has been recognized that the intake of calcium and calcium salt has a certain preventive effect on periodontal disease. However, as described above, periodontal disease caused by periodontal pathogen causing periodontal disease. It is difficult to expect a prophylactic or therapeutic effect, as strong injurious stimulatory effects on tissues cannot be eliminated.
【０００６】上記の抗菌性植物抽出物のうち、大豆イソ
フラボン抽出物は、抗菌性を示す成分に加えて、さらに
天然の骨代謝改善作用を有する成分を豊富に含んでいる
ことが知られており、骨粗鬆症予防、全身の骨強化目的
ための内服の栄養補給剤として、カルシウム塩、ビタミ
ンＤとともに配合された実績をもち、米国では、商品名
OsteoSoy（ FreeLife社、米国）、Soylife（ Schouten
社、米国）として販売された実績をもつ。これらは一般
のカルシウム補給剤と同様に、内服用タブレット、カプ
セル、パウダー状であり、口腔内での作用効果や、歯周
病予防を目的として設計されたものではない。[0006] Among the above antibacterial plant extracts, the soybean isoflavone extract is known to contain abundant components having a natural bone metabolism improving effect in addition to components having antibacterial activity. Has been combined with calcium salts and vitamin D as an oral nutritional supplement for the prevention of osteoporosis and whole-body bone strengthening.
OsteoSoy (FreeLife, USA), Soylife (Schouten
Co., USA). These are, like general calcium supplements, tablets, capsules, and powders for internal use, and are not designed for the effects of oral treatment or for preventing periodontal disease.
【０００７】[0007]
【発明が解決しようとする課題】本発明は、安全性が高
く、且つ、実用的な歯周病予防又は歯周病進行予防食品
組成物を提供することを目的とする。SUMMARY OF THE INVENTION An object of the present invention is to provide a food composition which is highly safe and practical for preventing periodontal disease or preventing periodontal disease progression.
【０００８】[0008]
【課題を解決するための手段】本発明者は、カルシウム
塩と抗菌性植物抽出物の組み合わせおよび摂取方法につ
いて鋭意検討した結果、高溶解性カルシウム塩と抗菌性
植物抽出物とを含有する組成物を、高溶解性カルシウム
塩と抗菌性植物抽出物が口腔内で溶解乃至分散し、のち
嚥下摂取されるような食品とすることにより、意外にも
抗菌性植物抽出物が歯頸部に高濃度に付着滞留し、抗菌
活性が持続することを発見し、かかる抗菌性の持続によ
り、歯周病の原因である歯周病原菌の歯周組織に対する
刺激作用を取り除くことが可能となり、さらに、高溶解
性カルシウムも腸管を経て体内に吸収された後、効率的
に歯槽骨組織に蓄積され、歯周病を予防又は歯周病の進
行を予防する効果が極めて増強されることを見出し、本
発明を完成した。Means for Solving the Problems The present inventors have conducted intensive studies on the combination of calcium salt and an antibacterial plant extract and the method of ingesting the same. As a result, a composition containing a highly soluble calcium salt and an antibacterial plant extract was found. By dissolving or dispersing the highly soluble calcium salt and the antibacterial plant extract in the oral cavity and then swallowing the food, the antibacterial plant extract is unexpectedly highly concentrated in the cervix. It has been discovered that the antimicrobial activity persists, and that the antimicrobial activity persists. After calcium is also absorbed into the body through the intestinal tract, it is efficiently accumulated in the alveolar bone tissue, and it has been found that the effect of preventing periodontal disease or preventing the progression of periodontal disease is extremely enhanced, and the present invention completed.
【０００９】すなわち、本発明は、 項１ 抗菌性植物抽出物及び高溶解性カルシウムを含有
する歯周病予防又は歯周病進行予防食品組成物、 項２ 抗菌性植物抽出物が、油溶性甘草抽出物、大豆イ
ソフラボン抽出物、茶ポリフェノール抽出物から選ばれ
る１種または２種以上である項１記載の食品組成物、 項３ 高溶解性カルシウムが、グルコン酸カルシウム、
乳酸カルシウム、塩化カルシウム、グリセロリン酸カル
シウム、パントテン酸カルシウム、第一リン酸カルシウ
ムから選ばれる１種または２種以上である項１〜２のい
ずれかに記載の食品組成物、 項４ 高溶解性カルシウムが、グルコン酸カルシウムと
乳酸カルシウムの混合非晶質体である項１〜３のいずれ
かに記載の食品組成物、 項５ さらに、キシリトール、パラチニット、エリスリ
トール、マルチトール、ソルビトール、還元澱粉糖、還
元イソマルトオリゴ糖からなる群より選ばれる１種以上
の糖アルコールを含む項１〜４のいずれかに記載の食品
組成物、 項６ さらに、ビタミンＤ3、ビタミンＫ、カルシトニ
ン、イプリフラボンからなる群より選ばれる少なくとも
１種を含む項１〜５のいずれかに記載の食品組成物、 項７ 抗菌性植物抽出物が油溶性甘草抽出物、大豆イソ
フラボン抽出物、茶ポリフェノール抽出物から選ばれる
１種または２種以上であり、高溶解性カルシウムがグル
コン酸カルシウムと乳酸カルシウムの混合非晶質体であ
り、さらに第三リン酸カルシウムを含有するチュアブル
タブレットである項１記載の食品組成物に係るものであ
る。That is, the present invention relates to a food composition for preventing periodontal disease or preventing progression of periodontal disease, comprising: 1) an antibacterial plant extract and highly soluble calcium, and 2) an antibacterial plant extract comprising an oil-soluble licorice. Item 1. The food composition according to Item 1, which is one or more selected from an extract, soy isoflavone extract, and tea polyphenol extract, Item 3. The highly soluble calcium is calcium gluconate,
Item 4. The food composition according to any one of Items 1 to 2, which is one or more selected from calcium lactate, calcium chloride, calcium glycerophosphate, calcium pantothenate, and monobasic calcium phosphate. Item 5. The food composition according to any one of Items 1 to 3, which is a mixed amorphous form of calcium acid and calcium lactate. Item 5. Furthermore, xylitol, palatinit, erythritol, maltitol, sorbitol, reduced starch sugar, reduced isomaltoligosaccharide food composition according to any one of claim 1 to 4 comprising one or more sugar alcohols selected from the group consisting of, claim 6 further vitamin D 3, vitamin K, at least one selected from the group consisting of calcitonin, a ipriflavone Item 7. A food composition according to any one of Items 1 to 5, including a seed, Item 7. Antibacterial plant The extract is one or more selected from oil-soluble licorice extract, soy isoflavone extract, tea polyphenol extract, and highly soluble calcium is a mixed amorphous body of calcium gluconate and calcium lactate, Item 4. The food composition according to item 1, which is a chewable tablet further containing tribasic calcium phosphate.
【００１０】本発明において、「歯周病進行予防」と
は、歯周病になった場合に歯周病が進行するのを抑制乃
至防止することを意味する。In the present invention, "prevention of periodontal disease progression" means to suppress or prevent progression of periodontal disease when periodontal disease occurs.
【００１１】[0011]
【発明の実施の形態】本発明食品組成物に使用する抗菌
性植物抽出物としては、抗菌性を有する植物抽出物であ
れば特に限定されるものではないが、例えば、甘草（植
物名；グリチリザ・グラブラ、グリチリザ・インフラ
タ、グリチリザ・アラレアシス）根から抽出される油溶
性甘草抽出物（含有抗菌成分名；グラブリジン、グラブ
レン、リコカルコン）、緑茶から得られる茶ポリフェノ
ール抽出物（含有抗菌成分名；エピガロカテキン等）、
大豆から得られるイソフラボン抽出物（含有抗菌成分
名；ゲニステイン、ダイゼイン、ゲニスチン、ダイジ
ン）を用いるのが好ましい。BEST MODE FOR CARRYING OUT THE INVENTION The antibacterial plant extract used in the food composition of the present invention is not particularly limited as long as it is an antibacterial plant extract. For example, licorice (plant name; glycyliza) Oil-soluble licorice extract extracted from the roots of glabra, glitiliza infrata, glitiliza araleasis) (containing antibacterial components; glabridine, grabrene, lycochalcone), tea polyphenol extract obtained from green tea (containing antibacterial components; epigallo) Catechin),
It is preferable to use an isoflavone extract (containing antibacterial components; genistein, daidzein, genistin, daidzin) obtained from soybean.
【００１２】抗菌性植物抽出物は、単独で用いてもよ
く、また、２種以上を組合わせて用いてもよいが、組合
せて用いる場合は、油溶性甘草抽出物と茶ポリフェノー
ル抽出物、油溶性甘草抽出物と大豆イソフラボン抽出
物、茶ポリフェノール抽出物と大豆イソフラボン抽出
物、油溶性甘草抽出物と茶ポリフェノール抽出物と大豆
イソフラボン抽出物の組合せが好ましく、特に、油溶性
甘草抽出物と大豆イソフラボン抽出物、もしくは、茶ポ
リフェノール抽出物と大豆イソフラボン抽出物の組合せ
が好ましい。The antibacterial plant extract may be used alone or in combination of two or more. When used in combination, the oil-soluble licorice extract and tea polyphenol extract, oil A soluble licorice extract and a soy isoflavone extract, a combination of a tea polyphenol extract and a soy isoflavone extract, a combination of an oil-soluble licorice extract, a tea polyphenol extract and a soy isoflavone extract, and particularly, an oil-soluble licorice extract and a soy isoflavone An extract or a combination of a tea polyphenol extract and a soy isoflavone extract is preferred.
【００１３】本発明組成物における抗菌性植物抽出物の
使用量は、所望の効果が得られるものであれば特に限定
されるものではないが、組成物全量に対して抽出物乾燥
重量として、０.０００５〜１０重量％、特に０.００５
〜１重量％配合することが好ましい。The amount of the antibacterial plant extract used in the composition of the present invention is not particularly limited as long as the desired effect can be obtained. 0.0005 to 10% by weight, especially 0.005
It is preferable to mix 1% by weight.
【００１４】油溶性甘草抽出物は、例えば、特開平4-16
4021号公報に記載の方法を用いて得たものを使用するこ
とができる。すなわち、当該方法によれば、油溶性甘草
抽出物を、甘草またはその同属植物、好ましくはその根
を、有機溶媒（例えば、メタノール、エタノール、アセ
トン、酢酸エチル、クロロホルムなど）を用いて抽出す
ることにより得られる。抽出原料としては、生又は乾燥
植物体のいずれを用いてもよい。The oil-soluble licorice extract is described in, for example,
Those obtained by using the method described in JP-A-4021 can be used. That is, according to the method, the oil-soluble licorice extract is extracted from licorice or a plant belonging to the same genus, preferably the root thereof, using an organic solvent (eg, methanol, ethanol, acetone, ethyl acetate, chloroform, etc.). Is obtained by As a raw material for extraction, either a raw or dried plant may be used.
【００１５】本発明において、抗菌性植物抽出物として
油溶性甘草抽出物を使用する場合の使用量は、所望の効
果が得られるものであれば特に限定されるものではない
が、本発明組成物全量に対して抽出物乾燥重量として、
0.0005〜10重量％、特に0.005〜5重量％配合することが
好ましい。In the present invention, the amount of the oil-soluble licorice extract used as the antibacterial plant extract is not particularly limited as long as the desired effect can be obtained. As extract dry weight for the whole amount,
It is preferable to add 0.0005 to 10% by weight, particularly 0.005 to 5% by weight.
【００１６】大豆イソフラボン抽出物は、マメ科（Legu
minosae）の植物であるダイズ（Glycine max Merrill）
の種子、胚軸を原料とし、抗菌性活性のある有効成分と
して、ゲニステイン、ダイゼイン、およびこれらイソフ
ラボンの配糖体（ゲニスチン、ダイジン）を含んでお
り、例えば、特開昭62-126186号公報に記載された一般
的な方法により配糖体として得ることができ、本発明組
成物においては当該方法により得られた大豆イソフラボ
ン抽出物を用いるのが好ましい。また、本発明組成物に
おいては、当該方法に従って得られた抽出物を、特開平
1-258669号公報に記載の方法により、又は、精製段階で
酸加熱もしくはβ−グルクロニダーゼ酵素を用いて加水
分解することにより、抽出物に含まれるイソフラボン配
糖体を加水分解し、ゲニステインやダイゼイン含量を高
めて利用してもよい。The soy isoflavone extract was obtained from legumes (Legu
soybean (Glycine max Merrill)
It contains genistein, daidzein, and glycosides of these isoflavones (genistin, daidzin) as active ingredients having antibacterial activity, using the seeds and hypocotyls as raw materials. It can be obtained as a glycoside by the general method described, and it is preferable to use the soy isoflavone extract obtained by the method in the composition of the present invention. Further, in the composition of the present invention, the extract obtained according to the above method is
According to the method described in 1-258669, or by hydrolysis using an acid heating or β-glucuronidase enzyme in the purification step, hydrolyze the isoflavone glycosides contained in the extract, genistein and daidzein content May be used.
【００１７】また、上記の抽出方法の一部によれば、大
豆イソフラボン抽出物がしばしば大豆由来の大豆蛋白質
と共に抽出されることがあるが、これら混合品の形態で
本発明組成物に配合することも可能である。According to a part of the above extraction method, the soybean isoflavone extract is often extracted together with the soybean-derived soybean protein. However, the soybean isoflavone extract may be added to the composition of the present invention in the form of a mixture thereof. Is also possible.
【００１８】本発明組成物において、大豆イソフラボン
抽出物を使用する場合の使用量は、本発明所期の効果が
得られるものであれば特に限定されるものではないが、
組成物全量に対して抽出物乾燥重量として、０.０００
１〜１０重量％、特に０.０１〜１重量％配合すること
が好ましい。The amount of the soy isoflavone extract used in the composition of the present invention is not particularly limited as long as the desired effect of the present invention can be obtained.
As extract dry weight based on the total amount of the composition, 0.000
It is preferable to add 1 to 10% by weight, particularly 0.01 to 1% by weight.
【００１９】茶ポリフェノール抽出物の原料としては、
一般的に飲用される茶（Camellia sinensis）をはじめ
とする緑茶、ウーロン茶、紅茶、プアール茶等から選択
可能であり、該抽出物は、抗菌活性成分としてエピガロ
カテキン類、エピカテキン類、ガロカテキン類を含有し
ている。これら茶ポリフェノール抽出物は、例えば、特
開昭６４−９０１２４号公報、特開平１−２６５０２３
号公報に記載されている方法にて入手が可能である。ま
た、これら公報に記載されたような茶ポリフェノール抽
出物は、食品素材として三井農林株式会社（商品名；ポ
リフェノン）、太陽化学株式会社（商品名；サンフェノ
ン）から販売されており、入手可能である。本発明にお
いては、これら市販の食品素材をそのまま使用すること
も可能である。The raw materials for the tea polyphenol extract include:
Green tea including commonly consumed tea (Camellia sinensis), oolong tea, black tea, pual tea, and the like can be selected, and the extract is used as an antibacterial active ingredient for epigallocatechins, epicatechins, and gallocatechins. It contains. These tea polyphenol extracts are described in, for example, JP-A-64-90124 and JP-A-1-265203.
It can be obtained by the method described in Japanese Patent Application Laid-Open Publication No. H10-26095. Also, tea polyphenol extracts as described in these publications are commercially available as food materials from Mitsui Norin Co., Ltd. (trade name: polyphenone) and Taiyo Kagaku Co., Ltd. (trade name: Sanphenon) and are available. . In the present invention, these commercially available food materials can be used as they are.
【００２０】本発明において、茶ポリフェノール抽出物
を使用する場合の使用量は、本発明所期の効果が得られ
るものであれば特に限定されるものではないが、本発明
組成物全量に対して抽出物乾燥重量として、０.００１
〜１重量％、特に０.０１〜０.５重量％配合することが
好ましい。In the present invention, the amount of tea polyphenol extract to be used is not particularly limited as long as the desired effect of the present invention can be obtained. 0.001 as dry weight of extract
１1% by weight, especially 0.01-0.5% by weight.
【００２１】抗菌性植物抽出物として油溶性甘草抽出物
と大豆イソフラボン抽出物とを組み合わせて配合する場
合には、重量比が１：１００〜１００：１となるよう
に、茶ポリフェノール抽出物と大豆イソフラボン抽出物
とを組み合わせて配合する場合には、配合比が１：１０
０〜１００：１となるように配合することが好ましい。When the oil-soluble licorice extract and the soybean isoflavone extract are combined and compounded as the antibacterial plant extract, the tea polyphenol extract and the soybean are mixed so that the weight ratio becomes 1: 100 to 100: 1. When combined with the isoflavone extract, the compounding ratio is 1:10.
It is preferable to mix them so as to be 0 to 100: 1.
【００２２】本発明食品組成物に用いる高溶解性カルシ
ウム塩は、カルシウム塩のうち水に対する溶解度が比較
的高いものであって本発明の所期の効果を達成できるも
のである限り限定されるものではないが、例えば、口腔
内唾液ｐＨ範囲（ｐＨ６．５−８．０）の水溶液におけ
る溶解濃度がカルシウム純分にして、２ｍｇ／ｍｌ以上
となるカルシウム塩であることが好ましい。本発明にお
いて用いる高溶解性カルシウム塩としては、具体的に
は、グルコン酸カルシウム、乳酸カルシウム、塩化カル
シウム、グリセロリン酸カルシウム、パントテン酸カル
シウム、第一リン酸カルシウムが挙げられる。The highly soluble calcium salt used in the food composition of the present invention is limited as long as the calcium salt has relatively high solubility in water and can achieve the desired effect of the present invention. However, for example, it is preferable to use a calcium salt having a dissolution concentration of 2 mg / ml or more as a pure calcium content in an aqueous solution in the oral saliva pH range (pH 6.5 to 8.0). Specific examples of the highly soluble calcium salt used in the present invention include calcium gluconate, calcium lactate, calcium chloride, calcium glycerophosphate, calcium pantothenate, and calcium monophosphate.
【００２３】さらに、本発明の高溶解性カルシウム塩に
は、グルコン酸溶液、乳酸溶液、塩酸溶液、リン酸溶液
から選ばれる少なくとも１種の酸味量を溶解した酸性溶
液中に、炭酸カルシウム又は水酸化カルシウムを添加溶
解して得られるカルシウム塩の過飽和溶液を、定法にし
たがい、オーブン乾燥、凍結乾燥、スプレー乾燥のいず
れかの方法を用いて乾燥することによって得られる高溶
解性のカルシウム混合物非晶質体をも含む。Further, the highly soluble calcium salt of the present invention contains calcium carbonate or water in an acidic solution in which at least one acidity selected from a gluconic acid solution, a lactic acid solution, a hydrochloric acid solution, and a phosphoric acid solution is dissolved. A highly soluble calcium mixture amorphous obtained by drying a supersaturated solution of a calcium salt obtained by adding and dissolving calcium oxide using any of oven drying, freeze drying and spray drying according to a standard method. Including the body.
【００２４】このような高溶解性カルシウム塩混合物の
非晶質体としては、グルコン酸カルシウムと乳酸カルシ
ウムの混合非晶質体を好ましく用いることができ、グル
コン酸カルシウム・乳酸カルシウム非晶質体は、商品名
グルカナールとしてアクゾノーベル社より市販されてい
る。グルコン酸カルシウム・乳酸カルシウム非晶質体
を、本発明組成物に用いる場合、グルコン酸カルシウム
と乳酸カルシウムとの配合比が、重量比にして９：１か
ら３：７の範囲内であることが望ましい。As the amorphous material of such a highly soluble calcium salt mixture, a mixed amorphous material of calcium gluconate and calcium lactate can be preferably used. It is commercially available from Akzo Nobel under the trade name Glucanal. When the calcium gluconate / calcium lactate amorphous material is used in the composition of the present invention, the mixing ratio of calcium gluconate and calcium lactate may be in the range of 9: 1 to 3: 7 by weight. desirable.
【００２５】本発明の高溶解性カルシウム塩には、上記
に例示したような高溶解度を有するカルシウム塩と、他
の水溶解性の低いカルシウム塩、例えば第三リン酸カル
シウム、炭酸カルシウム、クエン酸カルシウム等との混
合物も含まれる。なお、本発明において、第三リン酸カ
ルシウムとして牛骨粉を使用することができる。このよ
うな混合物を用いる場合には、高溶解度を有するカルシ
ウム塩が混合物に占める割合が２０％以上である必要が
ある。The highly soluble calcium salt of the present invention includes calcium salts having high solubility as exemplified above, and other calcium salts having low water solubility such as tribasic calcium phosphate, calcium carbonate, calcium citrate and the like. And mixtures thereof. In the present invention, bovine bone meal can be used as the tricalcium phosphate. When such a mixture is used, the proportion of the calcium salt having high solubility in the mixture needs to be 20% or more.
【００２６】本発明組成物における、高溶解性カルシウ
ム塩の使用量としては、組成物全量に対して１〜５０重
量％、特に５〜２５重量％配合することが好ましい。The amount of the highly soluble calcium salt used in the composition of the present invention is preferably 1 to 50% by weight, more preferably 5 to 25% by weight, based on the total amount of the composition.
【００２７】本発明組成物において、抗菌性植物抽出物
と高溶解性カルシウム塩の使用量は、本発明の所期の目
的を達成できる限り特に限定はされるものではないが、
例えば高溶解性カルシウム塩１００重量部に対して、抗
菌性植物抽出物１〜５重量部使用する場合に、最も歯周
病に対する予防又は治療効果が優れており特に好まし
い。The amounts of the antibacterial plant extract and the highly soluble calcium salt used in the composition of the present invention are not particularly limited as long as the intended object of the present invention can be achieved.
For example, when 1 to 5 parts by weight of an antibacterial plant extract is used with respect to 100 parts by weight of a highly soluble calcium salt, the effect of preventing or treating periodontal disease is most excellent, which is particularly preferable.
【００２８】本発明の食品組成物には、抗菌性植物抽出
物と高溶解性カルシウム塩以外に、通常食品組成物に含
まれるような添加物・食品素材、例えば、ｐＨ調整剤、
有機酸、糖アルコール、甘味料、香料、骨代謝ビタミ
ン、骨吸収抑制素材、歯垢形成抑制素材、口臭抑制素材
等を適宜配合することができる。The food composition of the present invention contains, besides the antibacterial plant extract and the highly soluble calcium salt, additives and food materials usually contained in the food composition, for example, a pH adjuster,
Organic acids, sugar alcohols, sweeteners, flavors, bone metabolism vitamins, bone resorption inhibiting materials, plaque formation inhibiting materials, bad breath inhibiting materials, and the like can be appropriately compounded.
【００２９】このような添加物乃至素材の具体例として
は、リン酸塩、リンゴ酸、クエン酸、乳酸、パントテン
酸、ソルビトール、キシリトール、エリスリトール、パ
ラチニット、パラチノース、マルチトール、還元デンプ
ン糖、還元イソマルトオリゴ糖等の異性化糖乃至糖アル
コール、ガムベース、アラビアガム、ゼラチン、セチル
メチルセルロース、サッカリンナトリウム、アスパルテ
ーム、ステアリン酸マグネシウム、グラニュー糖、粉
糖、水飴、微結晶セルロース、ｌ−メントール、ビタミ
ンＤ3等のビタミンＤ群、ビタミンＫ等のビタミンＫ
群、ビタミンＰ、リジン、マグネシウム塩、カルシトニ
ン、イプリフラボン等が挙げられる。Specific examples of such additives and materials include phosphate, malic acid, citric acid, lactic acid, pantothenic acid, sorbitol, xylitol, erythritol, palatinit, palatinose, maltitol, reduced starch sugar, reduced iso- isomerized sugar or sugar alcohols maltooligosaccharides such as gum base, gum arabic, gelatin, cetyl methyl cellulose, sodium saccharin, aspartame, magnesium stearate, granulated sugar, powdered sugar, starch syrup, microcrystalline cellulose, l-menthol, such as vitamin D 3 Vitamin D group, vitamin K such as vitamin K
Group, vitamin P, lysine, magnesium salt, calcitonin, ipriflavone and the like.
【００３０】これらの中でも、糖アルコールとしてキシ
リトール、パラチニット、エリスリトール、マルチトー
ル、ソルビトール、還元澱粉糖、還元イソマルトオリゴ
糖を使用することが好ましく、その他の添加物として、
ビタミンＤ3、ビタミンＫ、カルシトニン、イプリフラ
ボンを使用することが好ましい。Among these, it is preferable to use xylitol, palatinit, erythritol, maltitol, sorbitol, reduced starch sugar, reduced isomaltoligosaccharide as sugar alcohols, and as other additives,
Vitamin D 3, vitamin K, calcitonin, it is preferable to use the ipriflavone.
【００３１】これら添加物の使用量は特に限定されず、
使用の目的に応じて適宜選択することができる。The amount of these additives used is not particularly limited.
It can be appropriately selected according to the purpose of use.
【００３２】本発明組成物は、口腔に適用するものであ
って、摂取時に抗菌性植物抽出物が歯頸部に付着し、摂
取後にも、当該抗菌性植物抽出物が歯頚部表面に付着し
ているものであればその形態は限定されるものではな
い。例えば、摂取時に口中で咀嚼もしくは舐める等し
て、配合成分（抗菌性植物抽出物及び高溶解性カルシウ
ム塩）を口腔中で溶解、分散等させて抗菌性植物抽出物
が歯頸部の表面に付着できるようなものが挙げられる。The composition of the present invention is applied to the oral cavity. The antibacterial plant extract adheres to the cervix at the time of ingestion, and the antibacterial plant extract adheres to the cervix surface even after the ingestion. The form is not limited as long as it is satisfied. For example, at the time of ingestion, the ingredients (antibacterial plant extract and highly soluble calcium salt) are dissolved and dispersed in the mouth by chewing or licking in the mouth, and the antibacterial plant extract is placed on the surface of the cervical region. What can be attached is mentioned.
【００３３】ここで、抗菌性植物抽出物の付着は、抗菌
性植物抽出物が抗菌性を発揮するような充分な時間、歯
頚部表面に付着しているものであればよい。The antibacterial plant extract may be adhered to the cervical surface for a sufficient time for the antibacterial plant extract to exhibit antibacterial properties.
【００３４】また、本発明食品組成物は、口腔より摂取
した後組成物の全てを嚥下摂取してもよいし、抗菌性植
物抽出物及び高溶解性カルシウム塩以外の成分は嚥下摂
取しなくてもよい。The food composition of the present invention may be swallowed for all of the composition after ingestion from the oral cavity, and components other than the antibacterial plant extract and the highly soluble calcium salt may not be swallowed. Is also good.
【００３５】具体的には、トローチ、口中錠、チュアブ
ルタブレット、粒カプセル、顆粒、チューインガム、キ
ャンディ、グミキャンディー、ウエハース、ビスケット
等の食品に調製することが可能である。Specifically, it can be prepared into foods such as lozenges, lozenges, chewable tablets, granule capsules, granules, chewing gum, candy, gummy candy, wafers, biscuits and the like.
【００３６】本発明食品組成物は、上記各成分を各食品
における常法に従って調製することができる。The food composition of the present invention can be prepared from each of the above-mentioned components according to a conventional method for each food.
【００３７】本発明食品組成物の摂取量は、摂取するヒ
トの年齢、体重、性別、目的等に応じて適宜決定でき、
特に限定されるものではないが、通常、乾燥重量とし
て、１日２〜１０ｇを数回に分けて食後又は食間に摂取
されるのが好ましい。The amount of the food composition of the present invention to be taken can be appropriately determined according to the age, weight, sex, purpose, etc. of the human to be taken.
Although not particularly limited, it is generally preferable to take 2 to 10 g per day as a dry weight in several portions after or between meals.
【００３８】[0038]
【実施例】次に、実施例および試験例を挙げて、本発明
をさらに詳しく説明する。Next, the present invention will be described in more detail with reference to Examples and Test Examples.
【００３９】実施例１〜９並びに比較例Ａ１〜Ａ２、Ｂ
及びＣ 抗菌性植物抽出物として、油溶性甘草抽出物、大豆イソ
フラボン抽出物又は茶ポリフェノール抽出物を用い、高
溶解性カルシウムとして、グルコン酸カルシウム・乳酸
カルシウム非晶質体、又はグルコン酸カルシウム・乳酸
カルシウム非晶質体と第三リン酸カルシウムとの混合物
を用い、他の食品素材を表１に記載の通り配合して成る
チュアブルタブレットを常法に従って作製した。Examples 1 to 9 and Comparative Examples A1 to A2, B
And C: an oil-soluble licorice extract, soybean isoflavone extract or tea polyphenol extract as an antibacterial plant extract, and calcium gluconate / calcium lactate amorphous or calcium gluconate / lactic acid as highly soluble calcium. A chewable tablet comprising a mixture of an amorphous calcium body and tricalcium phosphate and other food ingredients as shown in Table 1 was prepared in accordance with a conventional method.
【００４０】比較例として、Ａ１、Ｂ及びＣにおいて
は、抗菌性植物抽出物のみを用いて、実施例と同様にし
てチュアブルタブレットを作製した。また、比較例Ａ２
では、高溶解性カルシウムの代わりに低溶解性カルシウ
ムである第三リン酸カルシウムのみを用い、他の食品素
材を表１に記載の通り配合して実施例と同様にしてチュ
アブルタブレットを作製した。As a comparative example, chewable tablets were prepared for A1, B and C in the same manner as in the example, using only the antibacterial plant extract. Comparative Example A2
In this example, chewable tablets were prepared in the same manner as in the examples by using only low-soluble calcium tribasic calcium phosphate instead of high-soluble calcium and mixing other food materials as shown in Table 1.
【００４１】[0041]
【表１】 [Table 1]
【００４２】実施例及び比較例で用いた各カルシウム素
材及びその他のカルシウム素材の水溶解度を表２に記載
しておく。Table 2 shows the water solubility of each calcium material and other calcium materials used in Examples and Comparative Examples.
【００４３】[0043]
【表２】 [Table 2]
【００４４】試験例１ 配合成分による抗菌性植物抽出物の歯質表面への付着性
を検討する目的で、下記の試験を行った。Test Example 1 The following test was conducted for the purpose of examining the adhesion of the antibacterial plant extract to the tooth surface by the compounding ingredients.
【００４５】上記のチュアブルタブレット各１個を、そ
れぞれ７．１ｍｌの人工唾液（成分組成；０．２１％リ
ン酸緩衝液、第三リン酸カルシウム０．０６％、０．２
４％塩化カリウム、硫酸カリウム０．０９％、アルブミ
ン０．５％、ｐＨ７．０溶液）に添加し、撹拌崩壊させ
て、３７℃にて３０分間回転スターラーバーにて撹拌
し、分散溶液を得た。その後、３７℃条件下で、ヒドロ
キシアパタイト円板(直径１３ｍｍ、厚み２ｍｍ。以降
「ＨＡＰ円板」と呼ぶ。)１枚を中層付近に浸漬し、３
０分後に取出した。ＨＡＰ円板の液滴を除去した後、円
板表面に付着している抗菌性植物抽出物を定量するため
に、円板を３０％メタノール溶液２ｍｌ中で２分間、激
しく振とう撹拌した後、遠心沈降させ、上清中にある抗
菌性植物抽出物を吸光度計にて測定した。その結果を、
図１に示した。Each of the above chewable tablets was placed in 7.1 ml of artificial saliva (component composition: 0.21% phosphate buffer, tribasic calcium phosphate 0.06%, 0.2 ml).
4% potassium chloride, 0.09% potassium sulfate, 0.5% albumin, pH 7.0 solution), disintegrate with stirring, and stir at 37 ° C. for 30 minutes with a rotary stir bar to obtain a dispersion solution. Was. Then, at 37 ° C., one hydroxyapatite disc (diameter 13 mm, thickness 2 mm; hereinafter referred to as “HAP disc”) is dipped near the middle layer, and
Removed after 0 minutes. After removing the droplets of the HAP disc, the disc was vigorously shaken and stirred for 2 minutes in 2 ml of a 30% methanol solution in order to quantify the antibacterial plant extract attached to the disc surface. After centrifugation, the antibacterial plant extract in the supernatant was measured with an absorbance meter. The result is
As shown in FIG.
【００４６】抗菌性植物抽出物のみよりなる比較例Ａ
１、Ｂ、Ｃと、さらに、第一リン酸カルシウム、グリセ
ロリン酸カルシウム、グルコン酸カルシウム・乳酸カル
シウム非晶質体又はグルコン酸カルシウム・乳酸カルシ
ウム非晶質体の混合物及びその他の食品素材を配合した
実施例１〜９とを比較した場合、実施例の各種の抗菌性
植物抽出物のＨＡＰ円板表面への付着量が（実施例１〜
５は、比較例Ａ１、実施例６〜７は比較例Ｂ、実施例８
〜９は比較例Ｃより）それぞれ２〜３倍量に増大したこ
とが図１に示される結果より判る。比較例として低溶解
性カルシウムである、第三リン酸カルシウムを配合した
比較例Ａ２では、これらの付着量増大効果は見られなか
った。Comparative Example A consisting only of an antibacterial plant extract
Example 1 in which 1, B and C were further blended with calcium phosphate monobasic, calcium glycerophosphate, calcium gluconate / calcium lactate amorphous or a mixture of calcium gluconate / calcium lactate amorphous and other food materials When compared with Comparative Examples 1 to 9, the amounts of the various antibacterial plant extracts of the examples adhered to the surface of the HAP disk (Examples 1 to 9).
5 is Comparative Example A1, Examples 6 and 7 are Comparative Example B, Example 8
It can be seen from the results shown in FIG. As a comparative example, in Comparative Example A2 in which tribasic calcium phosphate, which is a low-soluble calcium, was added, the effect of increasing the amount of these adhesions was not observed.
【００４７】試験例２ 抗菌性植物抽出物として大豆イソフラボン抽出物および
油溶性甘草抽出物を、また、高溶解性カルシウムとして
グルコン酸カルシウム・乳酸カルシウム非晶質体を含む
食品素材を表３に記載の通り配合してなる飲料水を調製
した。そして、ラット実験的歯周病モデルにより、本発
明品の歯周病予防効果を検討した。すなわち、ラット
（ウィスター系、雄、６週齢）２０匹を４群（各群５
匹）に分け、両群ともに、左右側臼歯（Ｍ２歯）にシル
クリガチャー（手術用絹糸）を結さつし、高シュクロー
ス粉末飼料を与えることにより、実験的に歯頸部にプラ
ークを蓄積させ、３週間で歯槽骨吸収を発症させる実験
的歯周病モデルを用いた。Test Example 2 Table 3 shows soy isoflavone extracts and oil-soluble licorice extracts as antibacterial plant extracts, and food materials containing amorphous calcium gluconate and calcium lactate as highly soluble calcium. A drinking water prepared as follows was prepared. The preventive effect of the product of the present invention on periodontal disease was examined using a rat experimental periodontal disease model. That is, 4 groups of 20 rats (Wistar, male, 6 weeks old) (5
In both groups, ligating silk ligature (surgical silk) to the left and right molars (M2 teeth) and feeding a high sucrose powder feed to experimentally accumulate plaque in the cervical region An experimental periodontal disease model was used to develop alveolar bone resorption in 3 weeks.
【００４８】この実験的歯周病モデルにおいて、第１群
（Ｎ＝５）には水道水を自由摂取させ、第２群（Ｎ＝
５）には、グルコン酸カルシウム・乳酸カルシウム非晶
質体を２％濃度となるよう溶解した水道水を自由摂取さ
せ、第３群（Ｎ＝５）には、大豆イソフラボン抽出物お
よび油溶性甘草抽出物を各々０．０５％濃度となるよう
添加した水道水を自由摂取させ、第４群（Ｎ＝５）に
は、グルコン酸カルシウム・乳酸カルシウム並びに大豆
イソフラボン抽出物および油溶性甘草抽出物を配合した
水道水を自由摂取させた（表３参照）。In this experimental periodontal disease model, the first group (N = 5) had free access to tap water and the second group (N = 5)
In 5), tap water in which calcium gluconate / calcium lactate amorphous was dissolved to a concentration of 2% was freely ingested. In the third group (N = 5), soybean isoflavone extract and oil-soluble licorice were used. The tap water to which each extract was added to a concentration of 0.05% was freely taken, and the fourth group (N = 5) was provided with calcium gluconate / calcium lactate, soy isoflavone extract and oil-soluble licorice extract. Free access to the blended tap water (see Table 3).
【００４９】[0049]
【表３】 [Table 3]
【００５０】３週間後に、常法に従って、左右側臼歯の
歯槽骨頂から歯頸部のエナメル質下端までの距離（０．
１ｍｍ単位）を計測し、歯槽骨吸収距離の群間比較を行
った。さらに、Ｍ２歯頸部に沈着しているプラーク沈着
面積（単位０．０１ｍｍ2）を実体顕微鏡写真により計
測した。Three weeks later, the distance from the alveolar crest of the left and right molars to the lower end of the enamel at the cervix (0.
(1 mm unit) was measured, and the alveolar bone resorption distance was compared between groups. Further, the plaque deposition area (unit: 0.01 mm 2 ) deposited on the M2 cervical region was measured by a stereomicrograph.
【００５１】その結果を図２及び図３に示す。The results are shown in FIGS. 2 and 3.
【００５２】水道水にグルコン酸カルシウム・乳酸カル
シウム非晶質体のみを加えた第２群は、水道水のみを摂
取させた第１群と比較し、歯槽骨吸収距離及びＭ２歯頸
部のプラーク面積は減少しておらず、グルコン酸カルシ
ウム・乳酸カルシウム非晶質体摂取の効果を示さなかっ
た。The second group in which only calcium gluconate / calcium lactate was added to tap water was compared to the first group in which only tap water was ingested, and the alveolar bone resorption distance and the plaque of M2 cervical region were compared. The area did not decrease, and the effect of ingesting calcium gluconate / calcium lactate amorphous body was not shown.
【００５３】水道水のみを摂取させた第１群と、水道水
に大豆イソフラボン抽出物および油溶性甘草抽出物を加
えて摂取させた第３群とを比較した場合、歯槽骨吸収距
離及びＭ２歯頸部のプラーク面積はわずかしか差がなか
った。When comparing the first group in which only tap water was taken and the third group in which soy isoflavone extract and oil-soluble licorice extract were added to tap water, the alveolar bone resorption distance and the M2 tooth were compared. The plaque area of the neck was only slightly different.
【００５４】これに対して、水道水にグルコン酸カルシ
ウム・乳酸カルシウム非晶質体のみを加えた第２群と、
該非晶質体に加えてさらに大豆イソフラボン抽出物及び
油溶性甘草抽出を添加して摂取させた第４群を比較した
場合、歯槽骨吸収距離及びＭ２歯頸部のプラーク面積に
明かな差を示した。即ち、該大豆イソフラボン抽出物お
よび油溶性甘草抽出物に該非晶質体を組み合わせたこと
により、歯周病に対する効果が明らかに増していること
が判る。On the other hand, a second group in which only calcium gluconate / calcium lactate amorphous material was added to tap water,
When the fourth group in which the soy isoflavone extract and the oil-soluble licorice extract were further added and taken in addition to the amorphous body, a clear difference was observed in the alveolar bone resorption distance and the plaque area of the M2 cervical region. Was. That is, it can be seen that the effect on periodontal disease is clearly increased by combining the soy isoflavone extract and the oil-soluble licorice extract with the amorphous substance.
【００５５】これらの結果より、高溶解性カルシウムと
抗菌性植物抽出物とを組み合わせて経口摂取した場合、
歯周病予防に極めて有用であることが示され、また、そ
の効果は、高溶解性カルシウムが、口腔内で抗菌性植物
抽出物の歯牙表面への付着性を高めた結果、歯周病原性
プラークの沈着防止効果を高めた結果であると考えられ
る。また、抗菌性植物抽出物の付着性が高められ、抗菌
性が持続することにより、腸管内で吸収された高溶解性
カルシウムの歯槽骨強化作用も高められていると考えら
れる。From these results, when oral intake of a combination of highly soluble calcium and an antibacterial plant extract,
It has been shown to be extremely useful in preventing periodontal disease, and its effect is due to the fact that highly soluble calcium enhances the adhesion of the antibacterial plant extract to the tooth surface in the oral cavity, This is considered to be the result of enhancing the effect of preventing plaque deposition. In addition, it is considered that the adhesion of the antibacterial plant extract is enhanced and the antibacterial property is maintained, and the alveolar bone strengthening action of the highly soluble calcium absorbed in the intestinal tract is also enhanced.
【００５６】次に他の実施例を示す。以下に示す例は本
発明を説明するために提示するものであり、本発明をこ
れらの例に限定するものではない。また、以下に示す例
は各剤形において特別な記載が無い限り常法により製造
されるものである。Next, another embodiment will be described. The following examples are provided to illustrate the invention and do not limit the invention to these examples. Further, the following examples are manufactured by a conventional method unless otherwise specified in each dosage form.
【００５７】実施例１０（顆粒） 高溶解性カルシウムと抗菌性植物抽出物を配合した顆粒
を、次の処方で作成した。Example 10 (Granules) Granules containing highly soluble calcium and an antibacterial plant extract were prepared according to the following formulation.
【００５８】 グルコン酸カルシウム・乳酸カルシウム非晶質体（８：２） ５０ 大豆イソフラボン抽出物 １０ 油溶性甘草抽出物 １０ 乳糖 ３９ アラビアガム １ 計１００ 重量部。Calcium gluconate / calcium lactate amorphous (8: 2) 50 Soy isoflavone extract 10 Oil-soluble licorice extract 10 Lactose 39 Arabic gum 1 Total 100 parts by weight.
【００５９】実施例１１ 高溶解性カルシウムと抗菌性植物抽出物を配合したチュ
アブルタブレットを、次の処方で作成した。Example 11 A chewable tablet containing highly soluble calcium and an antibacterial plant extract was prepared according to the following formulation.
【００６０】 グルコン酸カルシウム・乳酸カルシウム非晶質体（８：２） ２１．０ 第三リン酸カルシウム ３３．０ 油溶性甘草抽出物 １．５ キシリトール ４２．０ アラビアガム １．１ ステアリン酸マグネシウム １．１ 香料 ０．３ 計１００．０ 重量部 。Calcium gluconate / calcium lactate amorphous (8: 2) 21.0 Tricalcium phosphate 33.0 Oil-soluble licorice extract 1.5 Xylitol 42.0 Gum arabic 1.1 Magnesium stearate 1.1 Perfume 0.3 Total 100.0 parts by weight.
【００６１】実施例１２ 高溶解性カルシウムと抗菌性植物抽出物を配合したチュ
アブルタブレットを、次の処方で作成した。Example 12 A chewable tablet containing highly soluble calcium and an antibacterial plant extract was prepared according to the following formulation.
【００６２】 グルコン酸カルシウム・乳酸カルシウム非晶質体（８：２） １１．０ 炭酸カルシウム ４１．０ 大豆イソフラボン抽出物 １．０ キシリトール ４１．０ アラビアガム １．２ ショ糖脂肪酸エステル １．８ 香料 ３．０ 計１００．０ 重量部 。Amorphous calcium gluconate / calcium lactate (8: 2) 11.0 Calcium carbonate 41.0 Soy isoflavone extract 1.0 Xylitol 41.0 Gum arabic 1.2 Sucrose fatty acid ester 1.8 Fragrance 3.0 100.0 parts by weight in total.
【００６３】実施例１３ 高溶解性カルシウムと抗菌性植物抽出物を配合したチュ
ーインガムを、次の処方で作成した。Example 13 A chewing gum containing highly soluble calcium and an antibacterial plant extract was prepared according to the following formulation.
【００６４】 グルコン酸カルシウム・乳酸カルシウム非晶質体（８：２） ５．００ 油溶性甘草抽出物 ０．０５ ガムベース ２７．００ エリスリトール １０．００ キシリトール ４０．００ 還元麦芽糖水飴 1２．９５ 香料 ５．００ 計１００．０ 重量部 。Calcium gluconate / calcium lactate amorphous (8: 2) 5.00 Oil-soluble licorice extract 0.05 Gum base 27.00 Erythritol 10.00 Xylitol 40.00 Reduced maltose syrup 12.95 Fragrance 5. 00 100.0 parts by weight in total.
【００６５】実施例１４ 高溶解性カルシウムと抗菌性植物抽出物を配合したチュ
ーインガムを、次の処方で作成した。Example 14 A chewing gum containing highly soluble calcium and an antibacterial plant extract was prepared according to the following formulation.
【００６６】 グルコン酸カルシウム ５．０００ 大豆イソフラボン抽出物 １．０００ 茶ポリフェノール抽出物 ０．０５０ ビタミンＤ3 ０．００２ ガムベース ２０．０００ マルチトール ５４．８４８ パラチニット １０．０００ 還元澱粉分解物 ５．０００ グリセリン ３．０００ 香料 １．０００ アスパルテーム ０．１００ 計１００．０００重量部。Calcium gluconate 5,000 Soy isoflavone extract 1.000 Tea polyphenol extract 0.050 Vitamin D 3 0.002 Gum base 20.000 Maltitol 54.848 Palatinit 10.000 Reduced starch degradation product 5.000 Glycerin 3.000 Fragrance 1.000 Aspartame 0.100 Total 100.000 parts by weight.
【００６７】実施例１５ 高溶解性カルシウムと抗菌性植物抽出物を配合したキャ
ンディーを、次の処方で作成した。尚、グルコン酸カル
シウム・乳酸カルシウム非晶質体、キシリトール、油溶
性甘草抽出物、茶ポリフェノール抽出物、及び粉末香料
は粉体の状態でキャンディーセンターに配合した。Example 15 A candy containing highly soluble calcium and an antibacterial plant extract was prepared according to the following formulation. The calcium gluconate / calcium lactate amorphous material, xylitol, oil-soluble licorice extract, tea polyphenol extract, and powdered flavor were blended in a powdery state at a candy center.
【００６８】 グルコン酸カルシウム・乳酸カルシウム非晶質体(８：２) ５．００ 油溶性甘草抽出物 ０．０５ キシリトール ５．００ 茶ポリフェノール抽出物 ０．０５ パラチニット ７８．８６ マルチトール １０．００ アスパルテーム ０．０４ クエン酸 ０．５０ オイル香料 ０．２０ 粉末香料 ０．３０ 計１００．０００重量部。Amorphous calcium gluconate / calcium lactate (8: 2) 5.00 Oil-soluble licorice extract 0.05 Xylitol 5.00 Tea polyphenol extract 0.05 Palatinit 78.86 Maltitol 10.00 Aspartame 0.04 Citric acid 0.50 Oil flavor 0.20 Powder flavor 0.30 Total 100.000 parts by weight.
【００６９】実施例１６ 高溶解性カルシウムと抗菌性植物抽出物を配合したキャ
ンディーを、次の処方で作成した。Example 16 A candy containing highly soluble calcium and an antibacterial plant extract was prepared according to the following formulation.
【００７０】 乳酸酸カルシウム ５．００ 大豆イソフラボン抽出物 １．００ マルチトール ９０．８５ アスパルテーム ０．０５ ココアパウダー ３．００ 香料 ０．１０ 計１００．０００重量部。Calcium lactate 5.00 Soy isoflavone extract 1.00 Maltitol 90.85 Aspartame 0.05 Cocoa powder 3.00 Fragrance 0.10 Total 100.000 parts by weight.
【００７１】実施例１７ 高溶解性カルシウムと抗菌性植物抽出物を配合したトロ
ーチタイプの錠剤を作成した。Example 17 A troche-type tablet containing highly soluble calcium and an antibacterial plant extract was prepared.
【００７２】 クエン酸カルシウム・グルコン酸カルシウム非晶質体(３：７) １０．０００ 油溶性甘草抽出物 ０．１００ 牛骨粉第三リン酸カルシウム １５．０００ ビタミンＤ3 ０．００２ パラチニット ３３．０００ キシリトール ３３．８７３ カルボキシメチルセルロースナトリウム ２．０００ クエン酸 ２．０００ リンゴ酸 １．０００ アスパルテーム ０．０２５ 蔗糖脂肪酸エステル ２．０００ 香料 １．０００ 計１００．０００重量部。Calcium citrate / calcium gluconate amorphous (3: 7) 10.000 Oil-soluble licorice extract 0.100 Beef bone meal tribasic calcium phosphate 15.000 Vitamin D 3 0.002 Palatinit 33.000 Xylitol 33 0.873 sodium carboxymethylcellulose 2.00 citric acid 2.00 malic acid 1.00 aspartame 0.025 sucrose fatty acid ester 2.00 fragrance 1.000 total 100.000 parts by weight.
【００７３】実施例１８ 高溶解性カルシウムと抗菌性植物抽出物を配合したトロ
ーチタイプの錠剤を作成した。Example 18 A troche-type tablet containing highly soluble calcium and an antibacterial plant extract was prepared.
【００７４】 クエン酸カルシウム・グルコン酸カルシウム非晶質体(１：９) ２０．０００ 第三リン酸カルシウム ３０．０００ 大豆イソフラボン抽出物 １．０００ ビタミンＤ3 ０．００２ エリスリトール ２０．０００ パラチニット ２３．８６８ ステアリン酸マグネシウム １．０００ ココアパウダー ４．０００ アスサルファムＫ ０．０３０ 香料 ０．１００ 計１００．０００重量部。Calcium citrate / calcium gluconate amorphous (1: 9) 20.000 Calcium triphosphate 30.000 Soy isoflavone extract 1.000 Vitamin D 3 0.002 Erythritol 20.000 Palatinit 23.868 Stearin Magnesium acid acid 1.000 Cocoa powder 4.000 Assulfam K 0.030 Fragrance 0.100 Total 100.000 parts by weight.
【図１】 試験例１の結果を示す図である。FIG. 1 is a diagram showing the results of Test Example 1.
【図２】 試験例２の歯槽骨吸収距離を示す図である。FIG. 2 is a view showing the alveolar bone resorption distance in Test Example 2.
【図３】 試験例２のプラーク沈着面積を示す図であ
る。FIG. 3 is a view showing a plaque deposition area in Test Example 2.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 ＦＩ Ａ６１Ｋ 33/06 ＡＤＤ Ａ６１Ｋ 33/06 ＡＤＤ 35/78 ＡＣＫ 35/78 ＡＣＫ ＡＤＺ ＡＤＺ ──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 33/06 ADD A61K 33/06 ADD 35/78 ACK 35/78 ACK ADZ ADZ
Claims (7)
ムを含有する歯周病予防又は歯周病進行予防食品組成
物。1. A food composition for preventing periodontal disease or preventing periodontal disease progression, comprising an antibacterial plant extract and highly soluble calcium.
物、大豆イソフラボン抽出物、茶ポリフェノール抽出物
から選ばれる１種または２種以上である請求項１記載の
食品組成物。2. The food composition according to claim 1, wherein the antibacterial plant extract is one or more selected from an oil-soluble licorice extract, a soybean isoflavone extract, and a tea polyphenol extract.
シウム、乳酸カルシウム、塩化カルシウム、グリセロリ
ン酸カルシウム、パントテン酸カルシウム、第一リン酸
カルシウムから選ばれる１種または２種以上である請求
項１〜２のいずれかに記載の食品組成物。3. The highly soluble calcium is one or more kinds selected from calcium gluconate, calcium lactate, calcium chloride, calcium glycerophosphate, calcium pantothenate, and calcium monophosphate. A food composition according to claim 1.
シウムと乳酸カルシウムの混合非晶質体である請求項１
〜３のいずれかに記載の食品組成物。4. The highly soluble calcium is a mixed amorphous body of calcium gluconate and calcium lactate.
A food composition according to any one of claims 1 to 3.
エリスリトール、マルチトール、ソルビトール、還元澱
粉糖、還元イソマルトオリゴ糖からなる群より選ばれる
１種以上の糖アルコールを含む請求項１〜４のいずれか
に記載の食品組成物。5. The method of claim 1, further comprising: xylitol, palatinit,
The food composition according to any one of claims 1 to 4, comprising one or more sugar alcohols selected from the group consisting of erythritol, maltitol, sorbitol, reduced starch sugar, and reduced isomaltoligosaccharide.
ルシトニン、イプリフラボンからなる群より選ばれる少
なくとも１種を含む請求項１〜５のいずれかに記載の食
品組成物。6. The food composition according to claim 1, further comprising at least one selected from the group consisting of vitamin D 3 , vitamin K, calcitonin, and ipriflavone.
大豆イソフラボン抽出物、茶ポリフェノール抽出物から
選ばれる１種または２種以上であり、高溶解性カルシウ
ムがグルコン酸カルシウムと乳酸カルシウムの混合非晶
質体であり、さらに第三リン酸カルシウムを含有するチ
ュアブルタブレットである請求項１記載の食品組成物。7. The antimicrobial plant extract is an oil-soluble licorice extract,
One or two or more selected from soy isoflavone extract and tea polyphenol extract, wherein the highly soluble calcium is a mixed amorphous body of calcium gluconate and calcium lactate, and further comprises a chewable tablet containing tricalcium phosphate The food composition according to claim 1, which is
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP05235598A JP3648587B2 (en) | 1998-03-04 | 1998-03-04 | Periodontal disease prevention or periodontal disease progression food composition |
| PCT/JP1999/000981 WO1999044440A1 (en) | 1998-03-04 | 1999-03-01 | Food compositions for preventing periodontosis or preventing the progression of periodontosis and method for preventing or treating periodontosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP05235598A JP3648587B2 (en) | 1998-03-04 | 1998-03-04 | Periodontal disease prevention or periodontal disease progression food composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11243910A true JPH11243910A (en) | 1999-09-14 |
| JP3648587B2 JP3648587B2 (en) | 2005-05-18 |
Family
ID=12912514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP05235598A Expired - Lifetime JP3648587B2 (en) | 1998-03-04 | 1998-03-04 | Periodontal disease prevention or periodontal disease progression food composition |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP3648587B2 (en) |
| WO (1) | WO1999044440A1 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002121146A (en) * | 2000-10-13 | 2002-04-23 | Sunstar Inc | Preparation for preventing periodontal disease |
| JP2002121133A (en) * | 2000-10-13 | 2002-04-23 | Sunstar Inc | Tablet dissolving in oral cavity for prophylaxis of periodontal disease |
| JPWO2003037316A1 (en) * | 2001-10-11 | 2005-02-17 | 株式会社カネカ | Peroxisome proliferator-responsive receptor ligand agent and method for producing the same |
| WO2005046702A1 (en) * | 2003-09-19 | 2005-05-26 | Sunstar Inc. | Method of inhibiting alveolar resorption and peridental membrane loss and composition for internal use to be used therein |
| JP2006117601A (en) * | 2004-10-22 | 2006-05-11 | Nippon Zettoc Co Ltd | Composition for oral cavity |
| JP2009505644A (en) * | 2005-08-25 | 2009-02-12 | メーデラー ジュースヴァーレンフェアトリープス ゲーエムベーハー | Food additives for supplying mineral nutrients |
| JP2010159282A (en) * | 2000-12-12 | 2010-07-22 | Kaneka Corp | Composition for preventing or ameliorating multiple risk factor syndrome |
| JP2011236206A (en) * | 2010-04-16 | 2011-11-24 | Taisho Pharmaceutical Co Ltd | Directly compressed tablet containing ipriflavone |
| JP2015535220A (en) * | 2012-10-12 | 2015-12-10 | プレミア デンタル プロダクツ カンパニー | Topical oral supplement composition of vitamin D and ubiquinol |
| JP2016065005A (en) * | 2014-09-24 | 2016-04-28 | 株式会社東洋新薬 | Chondroitin preparation |
| US9877929B2 (en) | 2011-10-13 | 2018-01-30 | Premier Dental Products Company | Topical vitamin D and ubiquinol oral supplement compositions |
| US9877930B2 (en) | 2012-10-12 | 2018-01-30 | Premier Dental Products Company | Topical ubiquinol oral supplement compositions with amorphous calcium phosphate |
| JP2018104302A (en) * | 2016-12-22 | 2018-07-05 | 花王株式会社 | Granular dentifrice production method |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3921175B2 (en) * | 2001-04-02 | 2007-05-30 | わかもと製薬株式会社 | Composition for prevention and / or treatment of oral disease |
| WO2002091848A1 (en) | 2001-05-15 | 2002-11-21 | The Procter & Gamble Company | Confectionery compositions |
| AU2002311922A1 (en) | 2001-05-15 | 2002-11-25 | The Procter And Gamble Company | Oral care compositions |
| WO2005023210A1 (en) * | 2003-09-05 | 2005-03-17 | Kabushiki Kaisha Sangi | Recalcification-promoting agent, oral composition, food and drink |
| KR20070097581A (en) * | 2004-03-26 | 2007-10-04 | 아사히비루 가부시키가이샤 | A protectant of periodontal membranes |
| CN102696728A (en) * | 2012-05-31 | 2012-10-03 | 马健 | Method for making green tea biscuits |
| RU2763343C1 (en) * | 2020-09-15 | 2021-12-28 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Preventive caramel improving the remineralising potential of the oral fluid |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0637379B2 (en) * | 1987-01-19 | 1994-05-18 | サンスタ−株式会社 | Topical for treatment of periodontal disease |
| JPH04283518A (en) * | 1991-03-12 | 1992-10-08 | Kikkoman Corp | Agent for alleviating periodontosis |
| JPH05944A (en) * | 1991-06-21 | 1993-01-08 | Taiyo Kagaku Co Ltd | Composition for inhibiting adhesion of periodontosis causative microorganism |
| JPH0523153A (en) * | 1991-07-16 | 1993-02-02 | Food Design Gijutsu Kenkyu Kumiai | Drink, food or oral cavity product containing adlay extract |
| JPH05276873A (en) * | 1992-04-02 | 1993-10-26 | Fujimi Green Eng Kk | Dentifrice gum |
| JPH07309733A (en) * | 1994-05-19 | 1995-11-28 | Kanebo Ltd | Composition for oral cavity |
| JP3837172B2 (en) * | 1994-09-09 | 2006-10-25 | サントリー株式会社 | Inhibitor of adhesion to periodontal tissue of Porphyromonas gingivalis containing high molecular weight polyphenol as an active ingredient |
| JP2906215B2 (en) * | 1994-09-16 | 1999-06-14 | 日水製薬株式会社 | High concentration calcium containing liquid |
| JP3354764B2 (en) * | 1995-10-20 | 2002-12-09 | 独立行政法人 食品総合研究所 | Food and drink manufacturing method |
| JPH09143042A (en) * | 1995-11-24 | 1997-06-03 | Lion Corp | Composition for oral cavity |
| JPH10108648A (en) * | 1996-10-02 | 1998-04-28 | Advance Co Ltd | Residual food additive and oral cavity composition for suppressing dental caries and periodontal disease |
-
1998
- 1998-03-04 JP JP05235598A patent/JP3648587B2/en not_active Expired - Lifetime
-
1999
- 1999-03-01 WO PCT/JP1999/000981 patent/WO1999044440A1/en active Application Filing
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002121133A (en) * | 2000-10-13 | 2002-04-23 | Sunstar Inc | Tablet dissolving in oral cavity for prophylaxis of periodontal disease |
| JP2002121146A (en) * | 2000-10-13 | 2002-04-23 | Sunstar Inc | Preparation for preventing periodontal disease |
| JP2014177497A (en) * | 2000-12-12 | 2014-09-25 | Kaneka Corp | Composition for preventing or ameliorating multiple risk factor syndrome |
| JP2010159282A (en) * | 2000-12-12 | 2010-07-22 | Kaneka Corp | Composition for preventing or ameliorating multiple risk factor syndrome |
| JPWO2003037316A1 (en) * | 2001-10-11 | 2005-02-17 | 株式会社カネカ | Peroxisome proliferator-responsive receptor ligand agent and method for producing the same |
| US7888388B2 (en) | 2001-10-11 | 2011-02-15 | Kaneka Corporation | Peroxisome proliferator activated receptor ligand and process for producing the same |
| US7993684B2 (en) | 2003-09-19 | 2011-08-09 | Sunstar Inc. | Method of inhibiting alveolar bone resorption and periodontal membrane loss and composition for internal use to be used therein |
| WO2005046702A1 (en) * | 2003-09-19 | 2005-05-26 | Sunstar Inc. | Method of inhibiting alveolar resorption and peridental membrane loss and composition for internal use to be used therein |
| JPWO2005046702A1 (en) * | 2003-09-19 | 2007-05-24 | サンスター株式会社 | Method for inhibiting alveolar bone resorption and periodontal ligament loss and internal use composition used therefor |
| JP2006117601A (en) * | 2004-10-22 | 2006-05-11 | Nippon Zettoc Co Ltd | Composition for oral cavity |
| JP2009505644A (en) * | 2005-08-25 | 2009-02-12 | メーデラー ジュースヴァーレンフェアトリープス ゲーエムベーハー | Food additives for supplying mineral nutrients |
| JP2011236206A (en) * | 2010-04-16 | 2011-11-24 | Taisho Pharmaceutical Co Ltd | Directly compressed tablet containing ipriflavone |
| US9877929B2 (en) | 2011-10-13 | 2018-01-30 | Premier Dental Products Company | Topical vitamin D and ubiquinol oral supplement compositions |
| JP2015535220A (en) * | 2012-10-12 | 2015-12-10 | プレミア デンタル プロダクツ カンパニー | Topical oral supplement composition of vitamin D and ubiquinol |
| US9877930B2 (en) | 2012-10-12 | 2018-01-30 | Premier Dental Products Company | Topical ubiquinol oral supplement compositions with amorphous calcium phosphate |
| JP2016065005A (en) * | 2014-09-24 | 2016-04-28 | 株式会社東洋新薬 | Chondroitin preparation |
| JP2018104302A (en) * | 2016-12-22 | 2018-07-05 | 花王株式会社 | Granular dentifrice production method |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999044440A1 (en) | 1999-09-10 |
| JP3648587B2 (en) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3648587B2 (en) | Periodontal disease prevention or periodontal disease progression food composition | |
| CA2330128C (en) | Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis | |
| US7993684B2 (en) | Method of inhibiting alveolar bone resorption and periodontal membrane loss and composition for internal use to be used therein | |
| EP0842664B1 (en) | Zinc-containing compositions for oral administration including a copper compound and an aminoacid | |
| JP4390428B2 (en) | Calcium-containing tissue strengthening agent | |
| US8440219B2 (en) | Reduced-odor thiol compositions | |
| WO2003092666A1 (en) | Calcium-containing tissue strengthening agents and use thereof | |
| EP1508335B1 (en) | Compositions comprising a cocoa fraction for use in the treatment of periodontitis caused by bacteria belonging to genus porphyromonas, prevotella, fusobacterium or actinobacillus | |
| JP5977835B2 (en) | Ivory tubule sealant | |
| JP3459932B2 (en) | Anti-osteoporosis composition | |
| CN112236148A (en) | Composition for preventing or treating oral diseases | |
| EP2092834A1 (en) | Methods and compositions of sphingolipid for preventing treating microbial infections | |
| EP1677627B1 (en) | Dietetic preparation with hyaluronate for treatment of osteoporosis | |
| JP2002121133A (en) | Tablet dissolving in oral cavity for prophylaxis of periodontal disease | |
| US20050152852A1 (en) | Use of antibacterial component extracted from cacao mass for inhibiting the growth of periodontal bacteria | |
| JP2002020278A (en) | Chewing gum for preventing cancer of oral cavity | |
| KR100445994B1 (en) | A promoting composition for re-calcification of teeth | |
| JP2002121146A (en) | Preparation for preventing periodontal disease | |
| KR0158756B1 (en) | Chewing gum composition and process for preparing it | |
| JP2005112852A (en) | Internal medicinal composition for inhibiting gingival inflammation and periodontal membrane loss | |
| WO2013176272A1 (en) | Agent for the prevention and/or improvement of periodontal disease | |
| US20070292534A1 (en) | Antacid and breath freshening composition | |
| CA2591350A1 (en) | Antacid and breath freshening composition | |
| MXPA99004186A (en) | Chewing gum containing colloidal bismuth subcitrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040818 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041015 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050119 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050131 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080225 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090225 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090225 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100225 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110225 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110225 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120225 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130225 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140225 Year of fee payment: 9 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |